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Abstract
Separating indolent from aggressive prostate cancer is an important clinical challenge for identifying patients eligible for
active surveillance, thereby reducing the risk of overtreatment. The purpose of this study was to assess prostate cancer
aggressiveness by metabolic profiling of prostatectomy tissue and to identify specific metabolites as biomarkers for
aggressiveness. Prostate tissue samples (n = 158, 48 patients) with a high cancer content (mean: 61.8%) were obtained using
a new harvesting method, and metabolic profiles of samples representing different Gleason scores (GS) were acquired by
high resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS). Multivariate analysis (PLS, PLS-DA) and
absolute quantification (LCModel) were used to examine the ability to predict cancer aggressiveness by comparing low
grade (GS = 6, n = 30) and high grade (GS$7, n = 81) cancer with normal adjacent tissue (n = 47). High grade cancer tissue
was distinguished from low grade cancer tissue by decreased concentrations of spermine (p = 0.0044) and citrate
(p = 7.73?1024), and an increase in the clinically applied (total choline+creatine+polyamines)/citrate (CCP/C) ratio
(p = 2.17?1024). The metabolic profiles were significantly correlated to the GS obtained from each tissue sample
(r = 0.71), and cancer tissue could be distinguished from normal tissue with sensitivity 86.9% and specificity 85.2%. Overall,
our findings show that metabolic profiling can separate aggressive from indolent prostate cancer. This holds promise for the
benefit of applying in vivo magnetic resonance spectroscopy (MRS) within clinical MR imaging investigations, and HR-MAS
analysis of transrectal ultrasound-guided biopsies has a potential as an additional diagnostic tool.
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Introduction
Currently there are no objective clinical tools that can
accurately discriminate aggressive from indolent prostate cancer.
The Gleason scoring system [1] is the most important prognostic
tool in treatment planning, but it is dependent on subjective factors
in the evaluation of aggressiveness and is limited by underestima-
tion due to under-sampling of biopsies. New diagnostic and
prognostic tools for evaluating prostate cancer aggressiveness are
therefore urgently needed. Metabolic alteration is an emerging
hallmark of cancer [2], and metabolic profiling of prostate tissue
using magnetic resonance spectroscopy (MRS) can provide
additional information about tumor behaviour [3], especially with
the possibility to translate findings from ex vivo tissue samples to
in vivo measurements in patients using MRS imaging (MRSI).
Metabolic differences between prostate cancer and normal
tissue are documented both in vivo by MRSI [4,5,6,7] and ex vivo
using high resolution magic angle spinning MRS (HR-MAS)
[8,9,10]. In some hospitals, MRSI has already been implemented
into clinical practice, making use of the (total choline+creatine+-
polyamines)/citrate (CCP/C) ratio or the (total choline+creatine)/
citrate (CC/C) ratio which is increased in malignant prostate tissue
[5,8,11,12]. The total choline signal measured in vivo can be
separated by HR-MAS into the choline-containing metabolites
[free choline (Cho), phosphocholine (PCho) and glyceropho-
sphocholine (GPC)] [8,9,13]. Lactate and alanine are also reported
to be increased in cancer compared to normal tissues [10], while
the prostate-specific metabolites citrate and the polyamines
(spermine, spermidine, and putrescine) are found in lower
concentrations in cancer tissue [9,14].
HR-MAS is a well-established technique for analyzing bi-
ological tissue, leaving the samples unprocessed for subsequent
histopathological evaluation or other molecular methods such as
gene expression profiling [15,16]. We have previously confirmed
that there is a significant correlation between results from ex vivo
HR-MAS analyses and in vivo MRSI from spatially matched
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regions, proving that the translation from ex vivo to in vivo is valid
[17]. The overall aim of this study was to investigate the possibility
of assessing prostate cancer aggressiveness by HR-MAS analysis of
human prostate tissue, and to identify specific metabolites as
biomarkers for cancer aggressiveness. The study was performed
using fresh frozen tissue samples extracted from radical prostatec-
tomy specimens using a novel method allowing samples with a high
cancer content to be included [18]. Both metabolic profiles and
individual metabolite concentrations were used to discriminate
between the histologically determined Gleason score (GS) which
was evaluated from a cryosection of each tissue sample. The value
of HR-MAS as an additional tool to complement histopathological
scoring, and the improvement the results add to in vivo MRSI
examinations, will be discussed.
Materials and Methods
Patient and Tumor Characteristics
Since 2007, all prostate cancer patients at St. Olavs Hospital,
Trondheim University Hospital, Norway, scheduled for radical
prostatectomy have been invited to sign an informed consent
form to donate tissue for research. From each patient a 2 mm
transversal prostate tissue slice has been collected for storage in
the Regional Research Biobank of Central Norway. The study
has been approved by the Regional Committees for Medical
and Health Research Ethics (REC) Central, Norway, and the
Data Inspectorate of Norway. The current study includes 48
patients with no previous prostate cancer treatment and with
a tumor volume .5% of the gland, estimated by histopathol-
ogy. Patient characteristics are described in Table 1.
Harvesting Method and Sselection of HR-MAS Samples
On average 15 minutes after surgical removal of the prostate
gland, a tissue slice (2 mm) was obtained by transection through its
middle, perpendicularly to the urethra [18]. The slice was snap
frozen by clamping between two metal plates precooled in liquid
nitrogen and stored at 280uC. The two remaining halves were
stitched to a cork board, in order to avoid disturbances in the
histopathological evaluation of the surgical margin. After fixation
in formalin, both halves were further sliced (4 mm thick slices) and
paraffin embedded. Microscopic sections were made and stained
with hematoxylin, erythrosine and saffron (HES) for diagnostic
purposes. The HR-MAS samples were excised from the frozen
prostate slice using a novel harvesting method described by
Bertilsson et al. [18]. By using this method, summarized in
Figure 1, tissue samples of predetermined histopathological GS are
obtained from the slice. During sample extraction, the frozen
tissue slice was placed on an aluminium plate in direct contact with
liquid nitrogen, preventing the tissue from thawing and thus
reducing molecular degradation. Several samples from each slice
(range: 1–7 samples per slice (median: 3) depending on tumor size)
were selected from malignant areas of different GS and from
normal adjacent areas, using the HES stained slides from
neighboring tissue blocks as a guide. Thus, a total of 162 HR-
MAS samples was obtained. Normal adjacent samples are defined
as samples not showing signs of cancer, thus containing only
benign glandular and/or stromal tissue, and these samples were
excised as far away from the cancer as possible. To assess the GS
of each HR-MAS sample (2 mm thick), and to determine the
amount of cancer tissue, stroma, and glandular tissue, a 4 mm
cryosection was cut from one side of the extracted sample and
HES stained, and the tissue composition was evaluated by an
experienced pathologist specialized in uropathology before the
HR-MAS procedure. The samples were not thawed before the
Table 1. Characteristics of patients and prostate tissue samples.
Age (mean, range) Years 62.0(48–69)
Tumor volume (mean, range) Percentage of prostate gland 21.4 (5–90)
sPSA (mean, range) Before surgery (ng/mL) 10.5 (3.7–45.8)
After surgery (ng/mL)* 0.0 (0.0–1.0)
pT stage (patients) pT2a 2
pT2b 1
pT2c 29
pT3a 7
pT3b 7
unknown 2
Gleason score of HR MAS tissue samples
(samples/patients)a
0 47/41
3+3 30/21
3+4 22/19
4+3 20/15
4+4 16/12
3+5 2/1
5+3 1/1
4+5 12/9
5+4 8/5
*3 months after prostatectomya Several samples from each slice (range: 1–7 samples per slice depending on tumor size) were selected from locations corresponding to
cancer and normal areas, resulting in a total of 158 HR-MAS samples representing the different Gleason grades.
doi:10.1371/journal.pone.0062375.t001
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moment they go into the magnet, reducing additional freeze-thaw
effects. There are no studies stating that long-term storage at
280uC (up to 5 years) affect metabolism.
HR-MAS MRS Experiments
A PBS solution (3 ml) containing trimethylsilyl 3-propionic acid
sodium salt (TSP, 5 mM) and formate (25 mM) was added to
disposable Kel-F HR-MAS inserts (30 ml, Bruker Biospin,
Germany). Each prostate tissue sample (mean weight: 12.7 mg,
range: 3.0–21.9 mg) was transferred to a HR-MAS insert using
a sterile biopsy punch (2 mm, Miltex Gmbh, Germany), and the
insert was placed into the zirconium rotor (4 mm). HR-MAS was
performed on a Bruker Avance DRX600 (14.1 T) spectrometer
(Bruker BioSpin, Germany) equipped with a 1H/13C MAS probe.
Proton spectra were acquired at 4uC with a spin rate of 5 kHz.
Pulse-acquired spectra were obtained with a presaturation delay of
3.0s and acquisition time of 3.27s. A Carr-Purcell-Meiboom-Gill
(CPMG) spin echo sequence [90u-(t-180u-t)n –acquisition] was
used to suppress signals from lipids and macromolecules with an
effective echo time of 60 ms. One hundred and twenty-eight scans
over a spectral region of 10 kHz were collected into 64k points for
both sequences. The spectra were Fourier transformed with a line
broadening of 0.30 Hz. Chemical shifts were referenced to the
lactate peak (left peak of the doublet) at 1.336 ppm and a linear
baseline correction was applied (Topspin 3.1, Bruker Biospin,
Germany). Peak assignments were set according to the human
metabolomics database and previous published papers using HR
MAS on prostate tissue [9,10,19].
Multivariate Analysis
The spectral data between 1.46 and 4.66 ppm from the CPMG
spectra were used for multivariate analysis. The spectra were
normalized to an equal total area and peak aligned using icoshift
[20]. Signals from ethanol contamination (3.65–3.69 ppm) were
removed from the spectra together with those of lipid residuals at
1.60, 2.05, and 2.27 ppm. Preprocessing of the spectra was
performed in MATLAB 7.8.0 (The Mathworks, Inc., USA). In
addition to principal component analysis (PCA), partial least
squares (PLS) regression and PLS discriminant analysis (PLS-DA)
[21] were used to model the relationship between the MR spectra
and tumor/patient characteristics (tissue composition, GS, serum
PSA (sPSA), tumor volume, age and pT-stage). In order to avoid
Figure 1. The prostate sample harvesting method after radical prostatectomy. (A) The two HES-stained sections adjacent to the tissue slice.
(B) To localize the cancer and normal areas, micrographs of the two HES stained histological sections adjacent to the removed tissue slice were fused
with a photograph of the frozen tissue slice. The regions of interest were marked and transferred to a transparency sheet to be used as a map for
guiding sample extraction. (C) Cylindrical samples (3 mm diameter) for HR-MAS were excised from regions with normal tissue and cancer tissue with
different Gleason grades. The Gleason grade and the percentages of benign glandular tissue, stroma and cancer tissue were verified by analyzing
a 4 mm cryosection from each extracted sample. The figure is adapted from reference [36].
doi:10.1371/journal.pone.0062375.g001
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overfitting, double cross-validation was performed [22]. A PLS
model was built on training samples (80% of the data set) and used
to predict the status of independent test samples (the remaining
20%). The optimal number of LVs (latent variables) to use in the
model was determined by cross-validation of the training data and
applied independently to the test data. Both the inner and outer
loops of the double cross-validation procedure were repeated 20
times with different randomly chosen training and test sets, and
the average results are presented. As several samples from each
patient were analyzed, spectra from one patient were put in either
the training or the test set. The variable importance was evaluated
by variable importance in projection (VIP) scores [23]. Variables
with a VIP score greater than one are generally considered to be
important The classification results were validated by permutation
testing (n = 1000, significance for p,0.05) [22]. Multivariate
analyses were performed in MATLAB using PLS_toolbox 6.2.1
(Eigenvector Research, Inc., USA).
Absolute Quantification of Metabolites by LCModel
The pulse-acquired spectra were quantified using LCModel
[24,25] based on a novel basis set of 23 metabolites. The basis set
of simulated metabolite spectra was generated using NMRSIM
(Bruker BioSpin, Germany), and the metabolites were quantified
between 4.72 ppm and 20.8 ppm. The baseline was modeled
with a cubic spline function with a maximum of two knots, and
macromolecules were included in the fitting, simulated with single
peaks including prior knowledge of line width, chemical shift, and
relative amplitude. Small molecule metabolite and lipid chemical
shifts were set as mean values based on an initial assignment of
spectra from 10 samples of varying tissue type. For metabolites
where some peaks were not clearly resolved in these spectra (GPC,
GPE, glucose, and the amino acids), literature values were used
[26,27,28]. Ethanol, a contaminant in some samples, was included
in the basis set for a successful subsequent fitting with the
metabolite spectra. The metabolites were quantified according to
formate and the concentrations are reported as mmol/kg wet
weight. Full relaxation of formate was assured by using results
from T1 relaxation measurements performed on six additional
tissue samples.
Statistical Analysis of Metabolite Concentrations
Differences in metabolite concentrations between cancer and
normal adjacent tissue, and metabolic differences related to
aggressiveness (low grade (GS = 6) vs. high grade (GS$7)) were
analyzed by linear mixed models, accounting for the effect of
samples originating from the same patient. Individual comparison
of samples of GS 6, 7, and 8–9, in addition to differences between
samples of GS 3+4 and 4+3 were also tested. Analyses were
performed in R (version 2.14.1, R Foundation for Statistical
Computing) with the lme4 package [29]. The data were log
transformed prior to analysis in order to obtain normally
distributed residuals. The Benjamini and Hochberg false discovery
rate was used to correct for multiple testing. Adjusted p-
values,0.05 were considered significant.
Results
Samples
The PCA score plot of the CPMG spectra (n = 162) revealed
four outlying samples. These samples were removed from the data
set due to very high lipid concentrations and microscopic evidence
of severe inflammation. Of the 158 samples included in this study,
47 were shown to contain only normal prostate tissue components,
while 111 samples contained cancer tissue. The average cancer
content was 61.8% (range: 10–100%) and 30 cancer samples were
defined as low grade (GS 6) while 81 samples were defined as high
grade (GS 7–9). Sample and patient characteristics are summa-
rized in Table 1. Representative HR-MAS spectra and the
corresponding histopathological image of normal prostate tissue
and cancer tissue with different Gleason grades are shown in
Figure 2.
Metabolic Profiles Related to Clinical Parameters
The metabolic profiles were correlated to tissue composition
(percentage of benign glandular tissue: r = 0.67, stroma: r = 0.70,
and cancer: r = 0.77) (p,0.001). The metabolic profiles were not
significantly correlated to the patient’s sPSA level, tumor volume,
age or pT-stage (p.0.05).
Distinguishing Cancer and Normal Adjacent Tissue
Multivariate analysis. Based on the metabolic profiles,
cancer and normal samples were separated with 86% correct
classification using PLS-DA on independent test samples (sensi-
tivity 86.9%, specificity 85.2%, p,0.001). A PLS model correlat-
ing the metabolic profiles to GS (Figure 3, A-B) separates the
normal adjacent tissue samples from the cancer tissue samples.
The loadings showed decreased levels of citrate, taurine and
creatine, and an increase in GPC, PCho, Cho, and glycine in
cancer compared to normal tissue.
Absolute quantification by LCModel. The quantified
metabolite concentrations in cancer and normal tissue samples
(n = 153) are shown in Table 2. Five spectra were not quantified
due to insufficient fitting caused by high lipid signals.
Distinguishing Low Grade (GS = 6) and High Grade
Cancer Tissue (GS$7); Correlation with the Gleason
System
Multivariate analysis. Metabolic profiles were correlated to
GS with a correlation coefficient of r = 0.71 using PLS regression
analysis (p,0.001) (Figure 3, A-B). When analyzing only the
cancer samples, the metabolic profiles were correlated to GS with
a correlation coefficient of r = 0.45 (p,0.001) (Figure 3, C-D).
When dividing the samples into normal, high grade (GS$7) and
low grade (GS = 6), correct classification by PLS-DA was 85.8%
(sensitivity 89.3%, specificity 82.3%), 77.4% (sensitivity 84.4%,
specificity 70.5%), and 65.8% (sensitivity 64.1%, specificity
67.6%), respectively.
Absolute quantification by LCModel. The concentrations
of spermine and citrate were shown to be significantly different
between low grade and high grade cancers, while no significant
differences were detected for the other metabolites. The concen-
trations and statistical results for the significant metabolites are
summarized in Table 3. For further examination of the metabolite
concentrations related to aggressiveness, metabolic differences
between samples of GS 6, 7, and 8–9 were analyzed individually
(Table 3). No significant differences between GS 7 and GS 8–9
were detected for any of the metabolites. In addition, no significant
differences in metabolite concentrations were found between
samples of GS 3+4 and 4+3 (p.0.05). The correlations between
GS and the concentrations of spermine and citrate were r =20.36
and r =20.43, respectively.
The clinically relevant CCP/C ratio was significantly increased
in high grade compared to low grade cancer samples (Table 3). In
addition, a trend of different GPC/PCho ratios between low and
high grade cancer samples was detected (p = 0.08). When
examining metabolite concentrations related to aggressiveness,
the percentages of benign glandular, stroma, and cancer tissue
Biomarkers for Prostate Cancer Aggressiveness
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Figure 2. Representative HR-MAS spectra and corresponding HES stained prostate tissue samples with different Gleason grades.
Visual inspection of the spectra show decreased levels of polyamines (predominately spermine) and citrate, and increased levels of GPC, PCho, and
Cho with increasing tumor grade.
doi:10.1371/journal.pone.0062375.g002
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were included in the linear mixed models in order to correct for
differences in tissue composition. However, none of the tissue types
had a significant contribution to the statistical models (p.0.05),
and the results are presented without correction for tissue
composition.
Discussion
In this study performed using prostate tissue with high cancer
content, we have shown the possibility to separate low grade from
high grade prostate cancer using metabolic profiling. Decreased
concentrations of citrate and spermine were shown to be valid MR
tissue biomarkers for prostate cancer aggressiveness, and the
metabolic profiles were significantly correlated to the GS showing
that aggressive cancers have an altered metabolism compared to
indolent cancer. Surprisingly, the choline containing components
were not increasing with GS, indicating that spermine and citrate
are the main contributors to the clinically applied CCP/C ratio
which increases with GS. In addition, this study confirms the
separation between cancer and normal tissue, and the HR-MAS
metabolic profiles were successfully separated with 86.0% correct
classification.
Many prostate cancer patients diagnosed with indolent disease
(GS 6) are eligible for inclusion in active surveillance programs. It
is therefore desirable to separate this group from patients with
higher grade cancers. Citrate concentrations could separate
samples with GS 6 from both GS 7 and 8–9, while the difference
in spermine concentrations was only significant between GS 6 and
GS 8–9. Interestingly, none of the metabolites was significantly
different between samples with GS 7 and GS 8–9, indicating that
samples with GS 7 (intermediate risk patients) have a metabolic
pattern similar to higher grade cancers. This finding supports the
consensus that only patients with GS#6 should be included in
active surveillance programs. Patients with GS 4+3 have worse
prognosis than those with GS 3+4, however this study could not
separate these clinically relevant subgroups.
Normal prostate epithelial cells produce and accumulate a large
amount of citrate which is secreted as a major component of the
Figure 3. Prostate cancer metabolic profiles are correlated to aggressiveness. (A) PLS scores and (B) loadings of LV1 and LV2 from PLS
regression correlating the metabolic profiles to GS with a correlation coefficient r = 0.71. The cancer samples are separated from the normal samples
in the score plot, with the loadings showing metabolic alterations related to malignancy. Samples with GS 9 are almost completely separated from
normal adjacent samples in the score plot, while some samples with a lower score overlap with the normal ones. The PLSDA model explains 48.2% of
the x-variance and 53.7% of the y-variance (C) PLS scores and (D) the corresponding loading profile of LV1 from PLS regression of the cancer samples
only, correlating the metabolic profiles to GS with a correlation coefficient r = 0.45. The resulting model explains 20.0% of the x-variance and 27.4% of
the y-variance of the data. The loadings in (B) and (D) are colored according to their VIP score. S-ino; scyllo-inositol.
doi:10.1371/journal.pone.0062375.g003
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prostatic fluid. Compared to normal tissue, decreased levels of
citrate are previously observed in prostate cancer tissue by ex vivo
MRS [9]. Our study confirms and extends these findings by
demonstrating a significant negative correlation with GS, and
significant differences between low grade and high grade cancer
tissue, between samples of GS 6 and GS 7, and between GS 6 and
GS 8–9. This supports the highly clinically relevant hypothesis that
the citrate concentration can distinguish between aggressive and
indolent prostate cancer.
Our results confirm previous in vivo and ex vivo MRS studies
showing that a decrease in polyamines is associated with prostate
cancer [8,14,30,31]. Additionally, the very low putrescine
concentration in our study confirms that the polyamine peak
predominantly consists of spermine. Due to the significantly lower
concentration of spermine in high grade compared to low grade
tissue, we propose spermine as a discriminative MR biomarker for
prostate cancer aggressiveness, and a focus to this should be
considered using the CCP/C ratio in MRSI examinations. Today,
spermine cannot be fully separated from the choline peak using
MRSI, but due to rapid technological developments already in
progress and higher field strengths (7T) making separation possible
[32], polyamines and especially spermine are potential biomarkers
in clinical practice.
Surprisingly, there were no significant differences between high
grade and low grade prostate cancer in any of the quantified
choline- or ethanolamine-containing metabolites (Eth, PE and
GPE). Previous ex vivo studies have demonstrated significant
correlations between GS and choline and total choline [33], and
significantly higher concentrations of GPC in high grade
(GS$4+3) compared to low grade (GS#3+4) cancers [13], which
is not in accordance with our findings. We found a trend towards
significance for the GPC/PCho ratio (p = 0.0832), which indicates
a change in the choline-containing metabolites associated with
increased aggressiveness, however not detected when examining
the metabolites individually. Due to contradictory findings of
choline metabolism also in other types of cancers [34], the choline
metabolism related to cancer aggressiveness evidently needs
further evaluation.
Previous in vivo MRSI studies have concluded a trend towards
a correlation between the CCP/C ratio and prostate cancer
aggressiveness [12,35], and our study showed a highly significant
difference in the CCP/C ratio between low and high grade
cancers. Our findings on the individual metabolites, however,
indicate that the decreased CCP/C ratio observed in vivo is mainly
resulting from decreased citrate levels.
Although there was a correlation between the metabolic profiles
and tissue composition, correction for tissue composition in the
analysis of individual metabolite concentrations was not signifi-
cant. This indicates that the metabolic differences between high
Table 2. Metabolite concentrations (mmol/kg) in cancer and
normal prostate tissue samples.
Metabolite
Normal adjacent
samples Cancer samples p-valueb
(n = 47) (n = 106)
Median (IQR) Median (IQR)
Sperminea 1.92 (0.86–3.13) 1.22 (0.66–2.00) 0.022*
Putrescine 0.38 (0.00–0.97) 0.02 (0.00–0.25) 2.07?1024*
Choa 0.46 (0.32–0.64) 1.02 (0.65–1.59) 6.89?1029*
PChoa 0.34 (0.19–0.51) 0.70 (0.39–1.12) 5.68?1026*
GPCa 0.42 (0.25–0.51) 0.78 (0.48–1.17) 2.04?1026*
GPE 0.22 (0.00–0.42) 0 (0.00–0.51) 0.387
PEa 1.66 (1.10–2.39) 2.67 (1.90–3.69) 1.38?1025*
Eth 0.00 (0.00–0.06) 0.00 (0.00–0.21) 0.926
Lactatea 12.34 (9.79–16.71) 18.20 (13.90–24.45) 7.52?1025*
Alaninea 1.71 (1.22–2.09) 2.15 (1.65–2.79) 0.0014*
Glucose 0.90 (0.53–1.36) 0.00 (0.00–0.42) 5.70?10212*
Citratea 9.87 (5.14–14.32) 6.41 (3.34–9.46) 0.049*
Succinatea 0.38 (0.30–0.49) 0.59 (0.46–0.81) 1.20?1024*
Creatinea 2.43 (1.76–3.11) 2.09 (1.64–2.58) 0.820
Glutamatea 2.69 (2.28–3.56) 4.82 (3.61–6.88) 2.60?1029*
Glutaminea 1.98 (1.56–2.37) 2.74 (2.25–3.52) 1.78?1025*
Glycinea 1.53 (1.18–1.98) 2.50 (1.74–3.18) 2.04?1026*
Isoleucine 0.09 (0.02–0.12) 0.17 (0.08–0.27) 0.0017*
Leucine 0.24 (0.17–0.34) 0.46 (0.30–0.64) 2.04?1026*
Valine 0.21 (0.18–0.29) 0.38 (0.25–0.49) 7.66?1024*
Taurinea 5.70 (3.88–6.32) 4.34 (3.65–6.53) 0.918
Myo-inositola 8.82 (7.91–10.77) 9.22 (7.04–11.30) 0.435
Scyllo-inositola 0.36 (0.25–0.58) 0.43 (0.33–0.59) 0.459
Concentrations are reported as mmol/kg wet weight. * p,0.05.
aCrame´r Rao lower bound (CRLB, LCmodel uncertainty measure) lower than
20% of the concentration for more than 90% of the samples, which is
acceptable for quantification [37,38]. Higher CRLB values are the result of near
or actual absence of signals in some samples.
bP-values from Linear mixed models corrected for multiple testing by
Benjamini-Hochberg correction.
doi:10.1371/journal.pone.0062375.t002
Table 3. Metabolite concentrations (mmol/kg) and ratios in low grade (GS = 6) and high grade (GS$7) prostate cancer samples
and comparison between different GSs.
Metabolite/ratio Low grade (n = 29) High grade (n = 77) p-valuea GS GS GS
6 vs 7 6 vs 8–9 7 vs 8–9
Median (IQR) Median (IQR) (p-valuea) (p-valuea) (p-valuea)
Spermine 1.96 (1.23–3.72) 1.05 (0.54–1.57) 0.0044* 0.110 0.022* 0.769
Citrate 8.45 (7.20–14.82) 4.76 (2.95–7.78) 7.73?1024* 0.014* 0.005* 0.769
CCP/C 0.78 (0.62–0.95) 1.20 (0.80–2.16) 2.17?1024* 0.0016* 9.47?1024* 0.162
GPC/PCho 1.53 (1.01–2.15) 1.02 (0.64–1.78) 0.0832 0.082 0.089 0.734
Concentrations are reported as mmol/kg wet weight. a P-values from Linear mixed models corrected for multiple testing by Benjamini-Hochberg correction; * p,0.05.
doi:10.1371/journal.pone.0062375.t003
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and low grade prostate cancer samples are present independently
of tissue composition. It is however likely that samples with lower
cancer content would require statistical methods correcting for
tissue composition.
A strength of this study is the inclusion of patients from the
whole range of clinical stages, including patients with highly
aggressive cancers. A limitation is however that the low grade
tissue material (GS 6) was mainly acquired from patients having
more aggressive tumors in the vicinity, and this may have induced
metabolic perturbation in our low grade material. A sample cohort
including more samples from patients with pure low grade cancer
may provide even clearer metabolic differences between low and
high grade cancers.
Conclusion
Based on metabolic profiling of human prostate cancer samples
this study shows that low and high grade prostate cancer tissue can
be distinguished by the concentrations of spermine, citrate and the
CCP/C ratio. In the future, by analyzing larger patient cohorts,
concentration cut-off values can be determined for spermine and
citrate, and models based on the metabolic profiles can become
tools for assessing prostate cancer aggressiveness. HR-MAS is
feasible as a diagnostic supplementary tool for evaluating
transrectal ultrasound guided biopsies, providing metabolic
profiles that can predict tumor aggressiveness. Ultimately, the
translation from ex vivo measurements in tissue samples to a true
non-invasive in vivo examination, rendered possible by improve-
ments in MR technology, will be the main future goal. Thus, our
results demonstrate the value of MRS in clinical treatment
planning and as a tool for follow-up of patients included in active
surveillance programs.
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